Higher versus lower shockwave energy for trapezius pain · Randomized trial · 2018
Is stronger shockwave better for neck and shoulder muscle pain?
In this small trial, neck and shoulder muscle pain dropped from between 5 and 6 to about 3 out of 10 after two sessions of focused shockwave, one a week, at either a higher or a lower strength. Pain ended about the same in both groups. Neck-related disability scores ended lower with the higher strength.
Both strengths eased pain- adults with recent neck and shoulder muscle pain
- 30
- sessions, one a week
- 2
- weeks of follow-up after the last session
- 2
Good to know: Small trial (30 people, mostly young women). Everyone had a numbing injection before each session.
Park KD, Lee WY, Park MH, et al. Medicine, 2018 · Read the paper ↗
How this study worked
Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.
What happened
Neck and shoulder muscle pain
0–10 pain scale · start and 2 weeks after the last session
Start2 weeks after treatment
Show the numbers
| Group | People | Start | 2 weeks after treatment |
|---|---|---|---|
| Higher strength | 15 | 5.67 | 3 |
| Lower strength | 15 | 5.4 | 3.07 |
The treatment
Higher strength
Focused, once a week for 2 weeks
- Sessions
- 2, one a week
- Pulses
- 1,500 per session
- Strength
- 0.210mJ/mm²
- Numbing
- Local anaesthetic · 5 mL of 1% lidocaine under the skin before every session
- Device
- Dornier AR2
- Everyone also got
- Paracetamol if needed, up to 2 g a day
Lower strength
Focused, once a week for 2 weeks
- Sessions
- 2, one a week
- Pulses
- 1,500 per session
- Strength
- 0.068mJ/mm²
- Numbing
- Local anaesthetic · 5 mL of 1% lidocaine under the skin before every session
- Device
- Dornier AR2
- Everyone also got
- Paracetamol if needed, up to 2 g a day
Compared with: The same shockwave course at a lower strength
Settings are what each study used, not a prescription.
Who took part
30 adults (27 women; average age about 32) with pain in the muscle across the top of the shoulder and neck that began within the last three months.
hollow squares: no final score
Side effects
No major side effects were reported, and no one stopped because of side effects. Minor effects were not counted.
All the numbers and the full appraisal
Every reported result
The results, in numbers.
Upper-trapezius MPS diagnosed with tender taut-band nodule, referred pain and local twitch; pain onset within three months and numeric pain at least 4. Mean age was approximately 32; 27/30 participants were women and mean symptom duration about 8 weeks. This is not a chronic longstanding-pain cohort.
15 allocated and analyzed; no follow-up loss in this arm.
16 allocated; one follow-up loss; 15 analyzed.
Verbal numeric scale1 reported outcome
Pain intensity
Verbal numeric scale Points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| High energy | 15 | 5.67 (SD 1.63) | 3 (SD 1.56) |
| Low energy | 15 | 5.4 (SD 1.64) | 3.07 (SD 1.49) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
High versus low energy endpoint
Mann–Whitney U
No significant between-group difference.
Analysis details and source
Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.
Neck Disability Index1 reported outcome
Neck disability
Neck Disability Index Points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| High energy | 15 | 11.27 (SD 4.04) | 4.2 (SD 1.78) |
| Low energy | 15 | 9.2 (SD 3.75) | 6.47 (SD 2.48) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
High versus low energy endpoint
Mann–Whitney U
Higher energy favored.
Analysis details and source
Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.
Inclinometer6 reported outcomes
Neck flexion
Inclinometer Degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| High energy | 15 | 56.53 (SD 14.49) | 65.47 (SD 10.09) |
| Low energy | 15 | 53.8 (SD 10.56) | 55.93 (SD 11.07) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
High versus low energy endpoint
Mann–Whitney U
Higher energy favored.
Analysis details and source
Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.
Neck extension
Inclinometer Degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| High energy | 15 | 61.67 (SD 12.84) | 68.93 (SD 11.47) |
| Low energy | 15 | 67.93 (SD 13.46) | 72.2 (SD 13.88) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
High versus low energy endpoint
Mann–Whitney U
No significant between-group difference.
Analysis details and source
Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.
Rotation to affected side
Inclinometer Degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| High energy | 15 | 69.87 (SD 10.59) | 74.2 (SD 10.38) |
| Low energy | 15 | 71 (SD 10.64) | 74.4 (SD 8.79) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
High versus low energy endpoint
Mann–Whitney U
No significant between-group difference.
Analysis details and source
Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.
Rotation to unaffected side
Inclinometer Degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| High energy | 15 | 61.27 (SD 14.42) | 73 (SD 10.48) |
| Low energy | 15 | 62.33 (SD 13.75) | 71 (SD 11.67) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
High versus low energy endpoint
Mann–Whitney U
No significant between-group difference.
Analysis details and source
Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.
Bending to affected side
Inclinometer Degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| High energy | 15 | 46.4 (SD 7.52) | 55.13 (SD 9.72) |
| Low energy | 15 | 49.07 (SD 7.33) | 55.33 (SD 9.81) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
High versus low energy endpoint
Mann–Whitney U
No significant between-group difference.
Analysis details and source
Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.
Bending to unaffected side
Inclinometer Degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| High energy | 15 | 41.4 (SD 8.82) | 54.27 (SD 10.81) |
| Low energy | 15 | 39.87 (SD 7.41) | 48.13 (SD 8.83) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
High versus low energy endpoint
Mann–Whitney U
No significant between-group difference.
Analysis details and source
Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.
Algometer1 reported outcome
Pressure pain threshold
Algometer kg/cm²
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| High energy | 15 | 1.63 (SD 0.37) | 2.32 (SD 0.55) |
| Low energy | 15 | 1.67 (SD 0.49) | 2.05 (SD 0.55) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
High versus low energy endpoint
Mann–Whitney U
No significant between-group difference.
Analysis details and source
Means and SD as reported; endpoint test unadjusted for baseline, no effect CI reported.
How treatment was delivered
Dornier AR2 focused treatment to the upper-trapezius trigger point (the more painful side when both sides were affected): 1,500 pulses once weekly for two weeks, 0.210 mJ/mm² in the high-energy arm. All patients received 5 mL of 1% subcutaneous lidocaine before every session. Pulse frequency was not reported.
Lower-energy arm used 0.068 mJ/mm² with the same pulses, sessions and local anesthesia. Rescue acetaminophen up to 2 g/day was allowed; other conservative treatments were prohibited until follow-up. No sham group was included.
No major adverse effects or withdrawals due to side effects were reported; minor-event frequency was not tabulated. A Korean health-research grant is acknowledged, despite an inconsistent no-funding sentence in the front matter. Authors declared no commercial benefits or conflicts.
Only 15 analyzed per arm, predominantly young women, short follow-up and no sham limit generalization. NDI baseline differed numerically and comparisons used unadjusted endpoints. Multiple outcomes raise false-positive concerns. Equal lidocaine exposure may modify the shockwave response and cannot establish results without anesthesia. Figure 1 shows 31 randomized (15 high, 16 low), with one low-energy follow-up loss and 30 analyzed. Its final labels claiming 15 excluded from analysis in each arm contradict the analyzed counts and appear to be diagram errors.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Only 15 analyzed per arm, predominantly young women, short follow-up and no sham limit generalization. NDI baseline differed numerically and comparisons used unadjusted endpoints. Multiple outcomes raise false-positive concerns. Equal lidocaine exposure may modify the shockwave response and cannot establish results without anesthesia. Figure 1 shows 31 randomized (15 high, 16 low), with one low-energy follow-up loss and 30 analyzed. Its final labels claiming 15 excluded from analysis in each arm contradict the analyzed counts and appear to be diagram errors.
Source-linked critical reading
Randomized pilot trial with random-number block allocation and opaque envelopes; patients and follow-up assessors were blinded. Thirty participants were analyzed. The flow describes 37 assessed, six declining after symptom relief and one follow-up loss.
Technical source record
Full local PDF read; All 7 PDF pages; Methods; Results; Tables 1–3; Figure 1; Discussion including anesthesia limitation and pain-conclusion discrepancy; Funding; conflicts; references
Higher energy improved two functional measures in this small study, but did not outperform lower energy for pain. The findings support further research rather than choosing the highest intensity automatically.
Does higher-energy focused ESWT improve upper-trapezius myofascial pain and function more than lower energy?
Randomized pilot trial with random-number block allocation and opaque envelopes; patients and follow-up assessors were blinded. Thirty participants were analyzed. The flow describes 37 assessed, six declining after symptom relief and one follow-up loss. Figure 1 shows 31 randomized (15 high, 16 low), with one low-energy follow-up loss and 30 analyzed. Its final labels claiming 15 excluded from analysis in each arm contradict the analyzed counts and appear to be diagram errors.
Upper-trapezius MPS diagnosed with tender taut-band nodule, referred pain and local twitch; pain onset within three months and numeric pain at least 4. Mean age was approximately 32; 27/30 participants were women and mean symptom duration about 8 weeks. This is not a chronic longstanding-pain cohort.
Dornier AR2 focused treatment to the upper-trapezius trigger point (the more painful side when both sides were affected): 1,500 pulses once weekly for two weeks, 0.210 mJ/mm² in the high-energy arm. All patients received 5 mL of 1% subcutaneous lidocaine before every session. Pulse frequency was not reported.
Lower-energy arm used 0.068 mJ/mm² with the same pulses, sessions and local anesthesia. Rescue acetaminophen up to 2 g/day was allowed; other conservative treatments were prohibited until follow-up. No sham group was included.
Verbal numeric pain 0–10, NDI 0–50, pressure pain threshold in kg/cm² and six cervical range-of-motion directions were assessed before and two weeks after the last treatment. Tables 2–3 distinguish paired improvement from endpoint comparisons.
At follow-up pain was 3.00 versus 3.07 (p=.838), showing no higher-energy advantage. NDI was 4.20 versus 6.47 (p=.008), and flexion 65.47° versus 55.93° (p=.029), favoring higher energy. Pressure threshold and other movement directions did not differ significantly. The conclusion wording claiming superior pain relief overstates the actual between-group pain test.
No major adverse effects or withdrawals due to side effects were reported; minor-event frequency was not tabulated. A Korean health-research grant is acknowledged, despite an inconsistent no-funding sentence in the front matter. Authors declared no commercial benefits or conflicts.
Only 15 analyzed per arm, predominantly young women, short follow-up and no sham limit generalization. NDI baseline differed numerically and comparisons used unadjusted endpoints. Multiple outcomes raise false-positive concerns. Equal lidocaine exposure may modify the shockwave response and cannot establish results without anesthesia.
Findings concern two short-course focused regimens under local anesthesia in relatively recent MPS. They do not establish that more energy is universally better or that observed disability differences are durable.
A larger prespecified dose trial should adjust baseline outcomes, include a credible sham, report analgesic use and minor harms, and follow function for months with and without local anesthesia.
Read the original article.
High- versus low-energy extracorporeal shock-wave therapy for myofascial pain syndrome of upper trapezius: A prospective randomized single blinded pilot study.
Park KD, Lee WY, Park MH, Ahn JK, Park Y. · Medicine · 2018
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →